Real-world clinical characteristics and outcomes in patients with HER2-mutant non-small cell lung cancer (NSCLC) who received second-line treatment: A nationwide database analysis in Japan.

Abstract excerpt

BACKGROUND: Although human epidermal growth factor receptor 2 (HER2)-targeted therapies have been approved for HER2-mutant NSCLC, real-world outcome data especially in the second-line setting remains limited. METHODS: This non-interventional study utilized the Center for Cancer Genomics and Advanced Therapeutics national database to identify patients with HER2-mutant NSCLC who received second-line treatment in...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antineoplastic Combined Chemotherapy Protocols
• Share to Carcinoma, Non-Small-Cell Lung